Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review (Q34100675)

31 July 2017

1 reference

title

Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review (English)

1 reference

31 July 2017

0 references

1 reference

Malinowski JM

1

1 reference

PubMed ID

11110228

31 July 2017

Bolesta S

series ordinal

2

1 reference

31 July 2017

1 October 2000

1 reference

31 July 2017

Clinical Therapeutics

1 reference

31 July 2017

22

1 reference

31 July 2017

1151-68; discussion 1149-50

1 reference

31 July 2017

10

1 reference

Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983060-X

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983060-X

7 January 2021

Consensus Development Conference on Insulin Resistance. 5-6 November 1997. American Diabetes Association

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983060-X

7 January 2021

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983060-X

7 January 2021

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983060-X

7 January 2021

The short- and long-term effects of tumor necrosis factor-alpha and BRL 49653 on peroxisome proliferator-activated receptor (PPAR)gamma2 gene expression and other adipocyte genes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983060-X

7 January 2021

BRL 49653 blocks the lipolytic actions of tumor necrosis factor-alpha: a potential new insulin-sensitizing mechanism for thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983060-X

7 January 2021

Systemic exposure to rosiglitazone is unaltered by food

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983060-X

7 January 2021

Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983060-X

7 January 2021

Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983060-X

7 January 2021

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983060-X

7 January 2021

Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983060-X

7 January 2021

Hepatic failure in a patient taking rosiglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983060-X

7 January 2021

Thiazolidinediones: a new class of antidiabetic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983060-X

7 January 2021

Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983060-X

7 January 2021

Hepatocellular injury in a patient receiving rosiglitazone. A case report

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983060-X

7 January 2021

Rosiglitazone and hepatic failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983060-X

7 January 2021

10.1016/S0149-2918(00)83060-X

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

11110228